[HTML][HTML] Advances and challenges in immunoPET methodology
P Mohr, J van Sluis, MN Lub-de Hooge… - Frontiers in Nuclear …, 2024 - frontiersin.org
Immuno-positron emission tomography (immunoPET) enables imaging of specific targets
that play a role in targeted therapy and immunotherapy, such as antigens on cell …
that play a role in targeted therapy and immunotherapy, such as antigens on cell …
[HTML][HTML] [89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 …
CA Gallegos, Y Lu, JC Clements, PN Song… - Theranostics, 2024 - ncbi.nlm.nih.gov
Rationale: Novel immune-activating therapeutics for the treatment of glioblastoma
multiforme (GBM) have shown potential for tumor regression and increased survival over …
multiforme (GBM) have shown potential for tumor regression and increased survival over …
Optical imaging of in vivo adoptive T‐cell therapy: State of the art and challenges
Adoptive T‐cell therapy (ACT), which is an important type of live cell therapy, has achieved
unprecedented success in treating hematological malignancies. Recent studies have shown …
unprecedented success in treating hematological malignancies. Recent studies have shown …
[HTML][HTML] In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer …
S Pezzana, S Blaess, J Kortendieck, N Hemmer… - …, 2024 - pmc.ncbi.nlm.nih.gov
Increasing evidence emphasizes the pivotal role of CD4+ T cells in orchestrating cancer
immunity. Noninvasive in vivo imaging of the temporal dynamics of CD4+ T cells and their …
immunity. Noninvasive in vivo imaging of the temporal dynamics of CD4+ T cells and their …
The development process of 'fit-for-purpose'imaging biomarkers to characterize the tumor microenvironment
JJ Eertink, I Bahce, JC Waterton, MC Huisman… - Frontiers in …, 2024 - frontiersin.org
Immune-based treatment approaches are successfully used for the treatment of patients with
cancer. While such therapies can be highly effective, many patients fail to benefit. To provide …
cancer. While such therapies can be highly effective, many patients fail to benefit. To provide …
Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies
J Duvenhage, M Kahts, B Summers, JR Zeevaart… - Seminars in Nuclear …, 2024 - Elsevier
Zirconium-89 (89 Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of
3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for …
3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for …
The role of CD8 PET imaging in guiding cancer immunotherapy
J Zhang, B Du, Y Wang, Y Cui, S Wang… - Frontiers in …, 2024 - frontiersin.org
Currently, immunotherapy is being widely used for treating cancers. However, the significant
heterogeneity in patient responses is a major challenge for its successful application. CD8 …
heterogeneity in patient responses is a major challenge for its successful application. CD8 …